Login / Signup

Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials.

Elizabeth A RaetzPaola ReboraValentino ConterMartin SchrappeMeenakshi DevidasGabriele EscherichChihaya ImaiBarbara De MoerlooseKjeld SchmiegelowMelissa A BurnsSarah ElitzurRob PietersAndishe AttarbaschiAllen Eng-Juh YeohChing-Hong PuiJan StaryGunnar CarioNicole BodmerAnthony V MoormanBarbara BuldiniAjay VoraMaria Grazia Valsecchi
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Outcomes for patients age 21 years and younger with T-ALL and IF have improved in the contemporary treatment era with a DFS benefit among those undergoing HSCT in CR1. However, outcomes still lag considerably behind those who achieve remission at EOI, warranting investigation of new treatment approaches.
Keyphrases
  • young adults
  • ejection fraction
  • systemic lupus erythematosus
  • skeletal muscle
  • ulcerative colitis
  • replacement therapy
  • insulin resistance
  • glycemic control